Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy
Charles C. Wykoff, Muneeswar Gupta Nittala, Cecilia Villanueva Boone, Hannah J. Yu, Wenying Fan, Swetha Bindu Velaga, Justis P. Ehlers, Michael S. Ip, SriniVas R. Sadda, Charles C. Wykoff, Muneeswar G. Nittala, Cecilia Villanueva Boone, Hannah J. Yu, Brenda Zhou, Wenying Fan, Swetha Bindu Velaga, Alexander M. Rusakevich, Shaun I.R. Lampen, Michael S. Ip, SriniVas R. Sadda, Justis P. Ehlers, Sunil K. Srivastava, Jamie L. Reese, Amy Babiuch, Katherine Talcott, Natalia Figueiredo, Sari Yordi, Jenna Hach, William C. Ou, Richard H. Fish, Matthew S. Benz, Eric Chen, Rosa Y. Kim, James C. Major, Ronan E. O’Malley, David M. Brown, Ankoor R. Shah, Amy C. Schefler, Tien P. Wong, Christopher R. Henry, Sagar B. Patel, Vy T. Nguyen, Kelly L. Larkin
Topics & Concepts
AfliberceptMedicineDiabetic retinopathyOphthalmologyDosingRandomized controlled trialVisual acuityRanibizumabAdverse effectRetinalConfidence intervalInternal medicineBevacizumabDiabetes mellitusChemotherapyEndocrinologyRetinal Diseases and TreatmentsOcular Diseases and Behçet’s SyndromeRetinal Imaging and Analysis